Recent Notification from AOC Pharma S.à r.l.
Fagron has recently received important notification regarding changes in shareholding from AOC Pharma S.à r.l. This communication comes under Belgian laws that govern the disclosure of significant shareholdings in publicly traded companies. These rules are designed to ensure transparency in ownership structures and help maintain market integrity.
Details of the Notification
On a specific date, Fagron acknowledged that while there were changes in the chain of controlled undertakings associated with its shares, no critical notification thresholds were crossed. Specifically, AOC Pharma S.à r.l. maintained its share count in Fagron NV, which remains stable amidst the changes within its ownership structure.
Ownership Structure Insight
As per the notification received, AOC Pharma S.à r.l. directly holds 11.06% of the voting rights of Fagron NV. This data indicates a firm grasp of their position within the company and points towards their ongoing commitment as stakeholders. Notably, this stake has not fluctuated despite alterations in the chain of control.
Chain of Controlled Undertakings
The notification outlines AOC Pharma's connection through several corporate layers. AOC Pharma S.à r.l. is controlled by Active Ownership Fund SICAV-FIS SCS. This fund has appointed Active Ownership Corporation S.à r.l. as its alternative investment fund manager. A roadmap of control illustrates how this complex structure involves various entities and shareholders, indicating a detailed hierarchy where accountability and authority lie.
Understanding Voting Rights
AOC Pharma S.à r.l.'s cumulative total voting rights comprises 8,102,492 rights based on a denominator of 73,228,904. This signifies consistent backing and support for Fagron NV’s strategies and operational maneuvers within the competitive pharmaceutical landscape. Keeping up with percentages provides an overview of stakeholder influence and the potential power dynamics at play in corporate governance.
About Fagron
Fagron proudly stands as a leading global player in the field of pharmaceutical compounding, delivering individualized medications across hospitals, clinics, pharmacies, and directly to patients. Operating in over 30 countries, the company prioritizes tailored medicine solutions to enhance patient care and treatment outcomes.
The Belgian firm, with its headquarters situated in Nazareth and also listed on major European financial platforms Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR', continues to expand its operational footprint while surfing the waves of innovation and customer-centric approaches.
Further Information
If further questions arise regarding this notification or other matters concerning Fagron, stakeholders and interested parties can connect with Karin de Jong, the Chief Financial Officer, for a comprehensive understanding.
Frequently Asked Questions
What does the notification from AOC Pharma S.à r.l. signify?
The notification indicates that AOC Pharma S.à r.l. is maintaining its shareholding in Fagron NV without crossing any significant thresholds.
What percentage of voting rights does AOC Pharma S.à r.l. hold?
AOC Pharma S.à r.l. holds 11.06% of the total voting rights in Fagron NV.
How is the stake of AOC Pharma structured?
AOC Pharma's ownership structure is complex, involving several controlled undertakings and layers, primarily linked to Active Ownership Fund SICAV-FIS SCS.
What role does Fagron play in the pharmaceutical industry?
Fagron is a key player in pharmaceutical compounding, focusing on personalized medicine solutions across multiple global markets.
Who can I contact for more information about Fagron?
Karin de Jong, the Chief Financial Officer at Fagron, is the primary contact for inquiries related to the company and its operations.
